This page shows the latest Mission Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Halozyme Therapeutics has stopped its pivotal phase 3 study investigating its lead pancreatic cancer drug – and has announced a major restructuring of its workforce that has resulted in a 55% reduction ... Our mission now is to transition our strategy
macular degeneration (AMD), almost £3m for a Kings College London research team developing a T cell therapy for Crohn's disease and £1.9m for Cambridge start-up MISSION Therapeutics to
The therapeutics would work by controlling the pathways of gene expression that contribute to diseases. ... Dr Robert Gould, CEO and president of Epizyme, said: "Epizyme's mission is to develop personalised therapeutics for genetically-defined patients
More from news
Approximately 0 fully matching, plus 3 partially matching documents found.
1 trial of its lead candidate ARV-110 in prostate cancer earlier this year, ahead of rival biotechs such as C4 Therapeutics and Kymera Therapeutics as well as big pharma firms ... Other approaches are also in early-stage testing. Deubiquitylating (DUB)
Before she joined Crescendo, she held industry and corporate finance roles with private and listed SMEs, including PsiOxus Therapeutics, MISSION Therapeutics, OrthoMimetics and Cytomyx. ... Also a great contributor to the HBA at both the EU and UK level,
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Mission Therapeutics has appointed Dr Colin Goddard as its non-executive chairman, a role he will take up on January 1. ... Meanwhile, Mission Therapeutics' current chairman Dr Michael Moore will continue to sit on the firm's board and move into the
She joins from PsiOxus Therapeutics where she served as chief financial officer, and has also held a number of positions at Cytomyx Holdings, OrthoMimetics, and Mission Therapeutics. ... ambitious plans to create a high value pipeline of differentiated
David Luther joins with 25 years healthcare and pharmaceutical experience. Cambridge, UK-based Mission Therapeutics has appointed David Luther as chief financial officer. ... development. Dr Anker Lundemose, CEO of Mission Therapeutics, said: “David's
Cancer biotech MISSION Therapeutics has named Paul Wallace as chief business officer. ... The diversity of assets created is testimony to the rigour of MISSION's screening platform in this critically important, but hitherto difficult, area of drug
More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.
Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...